



Auto, automated; CGP, comprehensive genomic profiling; Dx, diagnosis; EHR, electronic health record; LIS, laboratory information system; MDT, multidisciplinary team; qual, quality; quant, quantity; QNS, quantity not sufficient; TAT, turnaround time.

**References:** 1. De Las Casas LE, Hicks DG. *Am J Clin Pathol.* 2021;155(6):781-792. doi:10.1093/ajcp/aqaa212 2. Plotkin E et al. *J Clin Oncol.* 2019;37(27\_suppl):49-49. doi:10.1200/JCO.2019.37.27\_suppl.49 3. Sadik H et al. *JCO Precis Oncol.* 2022;6(6):e2200246. doi:10.1200/PO.22.00246 4. Jennings LJ et al. *J Mol Diagn.* 2017;19(3):341-365. doi:10.1016/j.jmoldx.2017.01.011 5. Ascierto PA et al. *J Mol Diagn.* 2019;21(5):756-767. doi:10.1016/j.jmoldx.2019.05.004 6. Roberts MC et al. *JCO Precis Oncol.* 2021;5:PO.20.00431. doi:10.1200/PO.20.00431 7. American Cancer Society Cancer Action Network. Survey findings summary: understanding provider utilization of cancer biomarker testing across cancers. Accessed February 12, 2024. [https://www.fightcancer.org/sites/default/files/national\\_documents/provider\\_utilization\\_of\\_biomarker\\_testing\\_polling\\_memo\\_dec\\_2021.pdf](https://www.fightcancer.org/sites/default/files/national_documents/provider_utilization_of_biomarker_testing_polling_memo_dec_2021.pdf) 8. LUNgevity Foundation. Why should I talk to my doctor about comprehensive biomarker testing? Accessed February 9, 2024. <https://lungevity.canto.com/direct/document/mh82qvbv8fd7ileu3vjcc2pjc75/N2TCIH1HMCd1h8WukUAqWk2oiqY/original?content-type=application%2Fpdf&name=BiomarkerBrochure%28rev11-21%29.pdf> 9. Mikubo M et al. *J Thorac Oncol.* 2020;15(1):130-137. doi:10.1016/j.jtho.2019.09.081 10. Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. *Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine.* Graig LA, Phillips JK, Moses HL, eds. National Academies Press; 2016 11. El-Deiry WS et al. *CA Cancer J Clin.* 2019;69(4):305-343. doi:10.3322/caac.21560 12. Association of Community Cancer Centers. Precision medicine: integration of pathology with the cancer care team. Accessed February 1, 2024. [https://www.accc-cancer.org/docs/projects/landscape-of-pathology/pathology-patient-centered-care.pdf?sfvrsn=8173e1cb\\_2](https://www.accc-cancer.org/docs/projects/landscape-of-pathology/pathology-patient-centered-care.pdf?sfvrsn=8173e1cb_2) 13. Brown NA, Elenitoba-Johnson KSJ. *Annu Rev Pathol.* 2020;15:97-121. doi:10.1146/annurev-pathmechdis-012418-012735 14. Chakravarty D et al. *J Clin Oncol.* 2022;40(11):1231-1258. doi:10.1200/JCO.21.02767 15. Yu TM et al. *Clin Lung Cancer.* 2019;20(1):20-29.e8. doi:10.1016/j.clcc.2018.08.010 16. Pennell NA et al. *JCO Precis Oncol.* 2019;1-9. doi:10.1200/PO.18.00356 17. Anand K et al. *Clin Lung Cancer.* 2020;21(5):437-442. doi:10.1016/j.clcc.2020.05.007 18. Gosney JR et al. *ESMO Open.* 2023;8(4):101587. doi:10.1016/j.esmoop.2023.101587 19. Merker JD et al. *J Clin Oncol.* 2018;36(16):1631-1641. doi:10.1200/JCO.2017.76.8671 20. Rolfo C et al. *J Thorac Oncol.* 2021;16(10):1647-1662. doi:10.1016/j.jtho.2021.06.017 21. Pennell NA et al. *Am Soc Clin Oncol Educ Book.* 2019;39:531-542. doi:10.1200/EDBK\_237863 22. College of American Pathologists. Definition of synoptic BULLreporting. Accessed February 2, 2024. [https://documents.cap.org/documents/synoptic\\_reporting\\_definition\\_examples\\_v4.0.pdf](https://documents.cap.org/documents/synoptic_reporting_definition_examples_v4.0.pdf)